brilinta and Weed

{Fulldrug} and Weed

Authored by Pin Ng PhD

Edited by Hugh Soames

Advertising: We may earn a commission if you buy anything via our advertising or external links

brilinta and Weed


Most people who consume marijuana do so for its mood-altering and relaxing abilities. Weed gives people a high and allows them to relax. However, heavy consumption of weed can cause unwanted results. It can increase the anxiety and depression a person experiences, and it can interact with certain other drugs including brilinta. It is important to remember that interactions do occur with all types of drugs, to a great or lesser extent and this article details the interactions of mixing brilinta and Weed.


Mixing brilinta and Weed


Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca.

The most common side effects include dyspnea (difficulty breathing), bleeding and raised uric acid level in the blood.

It was approved for medical use in the European Union in December 2010, and in the United States in July 2011. In 2020, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

In the US, ticagrelor is indicated to reduce the risk of stroke in people with acute ischemic stroke or high-risk transient ischemic attack.

In the EU, ticagrelor, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in adults with acute coronary syndromes or a history of myocardial infarction and a high risk of developing an atherothrombotic event; and for the prevention of atherothrombotic events in adults with a history of myocardial infarction and a high risk of developing an atherothrombotic event.

Contraindications to ticagrelor are active bleeding, increased risk of bradycardia, concomitant therapy of ticagrelor and strong cytochrome P-450 3A (CYP3A4) inhibitors and moderate or severe hepatic impairment due to the risk of increased exposure to ticagrelor.

The common adverse effects are increased risk of bleeding (which may be severe) and shortness of breath (dyspnoea). Dyspnoea is usually transient and mild-to-moderate in severity, with a higher risk at < 1 month, 1–6 months and >6 months of follow up compared to clopidogrel. Discontinuation of therapy is rare, although some people do not persist or switch therapies. People who develop tolerable dyspnoea as a side effect of ticagrelor should be reassured to continue therapy, as it does not impact on the drug’s cardiovascular benefit and bleeding risk in acute coronary syndrome (ACS). Furthermore, two small subgroup analyses found no associations between ticagrelor and adverse changes in heart and lung function that may induce dyspnoea in stable coronary artery disease (CAD) and people with ACS without heart failure or significant lung disease.

Ventricular pauses ≥3 seconds may occur in people with ACS the first week of treatment, but are likely to be mostly asymptomatic and transient, without causing increased clinical bradycardic adverse events. Caution is recommended when using ticagrelor in people with advanced sinoatrial node disease. Allergic skin reactions such as rash and itching have been observed in less than 1% of people taking ticagrelor.

Inhibitors of the liver enzyme CYP3A4, such as ketoconazole and possibly grapefruit juice, increase blood plasma levels of ticagrelor and consequently can lead to bleeding and other adverse effects. Ticagrelor is a weak CYP3A4 inhibitor and is known to increase the concentrations of CYP3A4 metabolised medications; however, this interaction is unlikely to be clinically significant for atorvastatin and simvastatin at recommended doses. CYP3A4 inducers, for example rifampicin and possibly St. John’s wort, can reduce the effectiveness of ticagrelor. There is no evidence for interactions via CYP2C9.

The drug also inhibits P-glycoprotein (P-gp), leading to increased plasma levels of digoxin, ciclosporin and other P-gp substrates. Levels of ticagrelor and AR-C124910XX (the active metabolite of ticagrelor formed by O-deethylation) are not significantly influenced by P-gp inhibitors.

It is recommended to use low-dose aspirin (75–100 mg per day) with ticagrelor as dual antiplatelet therapy (DAPT). The combination of ticagrelor with aspirin doses greater than 100 mg per day may be less effective.

Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for people with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants). Ticagrelor was found to result in a lower risk of stroke at 90 days than clopidogrel, which requires metabolic conversion, among Han Chinese CYP2C19 loss-of-function carriers with minor ischemic stroke or TIA.

Ticagrelor is absorbed quickly from the gut, the bioavailability being 36%, and reaches its peak concentration after about 1.5 hours. The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring.

Plasma concentrations of ticagrelor are slightly increased (12–23%) in elderly people, women, people of Asian ethnicity, and people with mild hepatic impairment. They are decreased in people that self-identified as ‘black’ and those with severe renal impairment. These differences are not considered clinically relevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in people with severe hepatic impairment.

Consistently with its reversible mode of action, ticagrelor is known to act faster and shorter than clopidogrel. This means it has to be taken twice instead of once a day which is a disadvantage in respect of compliance, but its effects are more quickly reversible which can be useful before surgery or if side effects occur.

Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine. The substance has low solubility and low permeability under the Biopharmaceutics Classification System.

The PLATO trial concluded superiority of ticagrelor compared to clopidogrel in reducing the rate of death from vascular causes, MI, and stroke in people presenting with acute coronary syndromes. A post-hoc subgroup analysis of the PLATO trial suggested a reduction in total mortality with ticagrelor compared to clopidogrel in people with non-ST elevation acute coronary syndrome. However, this finding should only be considered exploratory as it was not a primary endpoint of the PLATO trial. Subsequent studies have also been underpowered in evaluating total mortality benefits with ticagrelor.

The PLATO trial found that ticagrelor use, in conjunction with low-dose aspirin (where tolerated), had better all-cause mortality rates than the same treatment plan with clopidogrel (4.5% vs. 5.9%, p<0.001) in treating people with acute coronary syndrome. People given ticagrelor were less likely to die from vascular causes, heart attack, or stroke, regardless of whether the treatment plan was invasive. While the patient group on ticagrelor had more instances of fatal bleeding and intracranial bleeding, the difference in cases was not considered significant (p=0.70). Rates of major bleeding were not significantly different between the two groups (7.9% vs. 7.7%, p=0.57). However, dyspnoea was significantly more likely in the ticagrelor group (13.8% vs. 7.8%, p<0.001). Premature discontinuation of the study drug was far more common in the ticagrelor group (23.4% vs. 21.5%, p=0.002), which could be due to adverse events (7.4% vs. 6.0%, p<0.001) or the patient’s unwillingness to continue (10.1% vs. 9.2%, p = 0.04).

The PLATO trial showed a statistically insignificant trend toward worse outcomes with ticagrelor versus clopidogrel among US participants in the study – who comprised 1627 of the total 13,326 participants. The hazard ratio actually reversed for the composite end point cardiovascular (death, MI, or stroke): 11.1% for participants given ticagrelor and 9.1% for participants given clopidogrel (HR = 1.27). It is important to note that even though there was a trend to worse outcomes in the US patient population, this trend was still classed as insignificant, and therefore should not affect patient use in the US population.

There is some conjecture in the safety and efficacy of ticagrelor within the Asian population, despite significant thrombotic benefits. A meta-analysis of observational studies in several Asian countries proposed that ticagrelor did not increase the risk of considerable bleeding events in Asian individuals. It is important to note that despite this being “real world” data, the study did not provide ethnic population demographics, leading to potential generalisation of data for Asian individuals. There is evidence to suggest that East Asian individuals are at a higher risk of bleeding events when using ticagrelor. Several recent meta-analyses of RCTs have been carried out in this population and although underpowered (more research is needed), the Asian Pacific Society of Cardiology Guidelines have taken these trials into account. The guidelines recommend that people of East Asian origin exercise caution and that treatment continuation after six months be based on net-clinical benefit.

In 2019, the results of the ISAR-REACT 5 trial was published, comparing ticagrelor and prasugrel in participants with acute coronary syndrome.

An in vitro assay and mouse model study published in 2019, showed antibacterial activity against antibiotic-resistant Gram-positive bacteria including Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE). This study used concentrations of ticagrelor for bactericidal activity that far exceeded those achieved by standard post Acute Coronary Syndrome (ACS) doses. A single-center retrospective cohort study demonstrated a significant reduction in gram-positive infection in the first year of ticagrelor compared with clopidogrel post ACS. Treatment with ticagrelor post PCI was also associated with a significantly lower absolute 1-year risk of S. aureus bacteraemia, sepsis, and pneumonia compared to clopidogrel in a nationwide observational study, however no causal inference can be drawn from the observational data.


Research has found that anxiety is one of the leading symptoms created by marijuana in users, and that there is a correlation between brilinta and Weed and an increase in anxiety.


Anyone mixing brilinta and weed is likely to experience side effects. This happens with all medications whether weed or brilinta is mixed with them. Side effects can be harmful when mixing brilinta and weed. Doctors are likely to refuse a patient a brilinta prescription if the individual is a weed smoker or user. Of course, this could be due to the lack of studies and research completed on the mixing of brilinta and Weed.


Heavy, long-term weed use is harmful for people. It alters the brain’s functions and structure, and all pharmaceuticals and drugs including brilinta are designed to have an impact on the brain. There is a misplaced belief that pharmaceuticals and medication work by treating only the parts of the body affected yet this is obviously not the case in terms of brilinta. For example, simple painkiller medication does not heal the injury, it simply interrupts the brains functions to receive the pain cause by the injury. To say then that two drugs, brilinta and Weed, dol not interact is wrong. There will always be an interaction between brilinta and Weed in the brain11.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from


One of the milder side effects of mixing brilinta and Weed is Scromiting. This condition, reportedly caused by mixing brilinta and Weed, describes a marijuana-induced condition where the user experiences episodes of violent vomiting, which are often so severe and painful that they cause the person to scream. The medical term for Scromiting by mixing brilinta and Weed is cannabinoid hyperemesis syndrome, or CHS.  For these reasons, some people choose to quit smoking weed.


It was first included in scientific reports in 2004. Since then, researchers have determined that Scromiting is the result of ongoing, long-term use of marijuana—particularly when the drug contains high levels of THC, marijuana’s main psychoactive ingredient. Some experts believe that the receptors in the gut become overstimulated by THC, thus causing the repeated cycles of vomiting.


In the long run, a person can become even more depressed. There is a belief that marijuana is all-natural and not harmful to a person’s health. This is not true and brilinta and weed can cause health issues the more a person consumes it.


How does Weed effect the potency of brilinta?


The way in which the body absorbs and process brilinta may be affected by weed. Therefore, the potency of the brilinta may be less effective. Marijuana inhibits the metabolization of brilinta. Not having the right potency of brilinta means a person may either have a delay in the relief of their underlying symptoms.


A person seeking brilinta medication that uses weed should speak to their doctor. It is important the doctor knows about a patient’s weed use, so they can prescribe the right brilinta medication and strength. Or depending on level of interactions they may opt to prescribe a totally different medication. It is important for the doctor to know about their patient’s marijuana use. Weed is being legalized around the US, so doctors should be open to speaking about a patient’s use of it.


Sideffects of brilinta and Weed


Many individuals may not realize that there are side effects and consequences to mixing brilinta and Weed such as:


  • Dizziness
  • Sluggishness
  • Drowsiness
  • Shortness of breath
  • Itching
  • Hives
  • Palpitations
  • Respiratory Depression
  • Cardiac Arrest
  • Coma
  • Seizures
  • Death


Interestingly, it is impossible to tell what effect mixing this substance with Weed will have on an individual due to their own unique genetic make up and tolerance. It is never advisable to mix brilinta and Weed due to the chances of mild, moderate and severe side effects. If you are having an adverse reaction from mixing brilinta and Weed it’s imperative that you head to your local emergency room. Even mixing a small amount of brilinta and Weed is not recommended.


Taking brilinta and Weed together


People who take brilinta and Weed together will experience the effects of both substances. Technically, the specific effects and reactions that occur due to frequent use of brilinta and weed depend on whether you consume more weed in relation to brilinta or more brilinta in relation to weed.


The use of significantly more weed and brilinta will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.


People who take both weed and brilinta may experience effects such as:


  • reduced motor reflexes from brilinta and Weed
  • dizziness from Weed and brilinta
  • nausea and vomiting due to brilinta and Weed


Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and brilinta leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.

Mixing weed and brilinta


The primary effect of weed is influenced by an increase in the concentration of the inhibitory neurotransmitter GABA, which is found in the spinal cord and brain stem, and by a reduction in its effect on neuronal transmitters. When weed is combined with brilinta this primary effect is exaggerated, increasing the strain on the body with unpredictable results.


Weed and brilinta affects dopamine levels in the brain, causing the body both mental and physical distress. Larger amounts of brilinta and weed have a greater adverse effect yet leading medical recommendation is that smaller does of brilinta can be just as harmful and there is no way of knowing exactly how brilinta and weed is going to affect an individual before they take it.


Taking brilinta and weed together


People who take brilinta and weed together will experience the effects of both substances. The use of significantly more brilinta with weed will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.


People who take both weed and brilinta may experience effects such as:


  • reduced motor reflexes from brilinta and weed
  • dizziness from weed and brilinta
  • nausea and vomiting of the brilinta


Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and brilinta leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.

Weed Vs brilinta


Taking brilinta in sufficient quantities increases the risk of a heart failure. Additionally, people under the influence of brilinta and weed may have difficulty forming new memories. With weed vs brilinta in an individual’s system they become confused and do not understand their environment. Due to the synergistic properties of brilinta when mixed with weed it can lead to confusion, anxiety, depression and other mental disorders. Chronic use of brilinta and weed can lead to permanent changes in the brain22.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from


brilinta Vs Weed


Studies investigating the effects of drugs such as brilinta and weed have shown that the potential for parasomnia (performing tasks in sleep) is dramatically increased when brilinta and weed are combined. Severe and dangerous side effects can occur when medications are mixed in the system, and sleep disorders are a common side effect of taking weed and brilinta together.


When a small to medium amount of weed is combined with brilinta, sleep disorders such as sleep apnea can occur. According to the latest data from the US Centers for Disease Control and Prevention (CDC) most ER visits and hospitalizations caused by too much weed were associated with other substances such as brilinta.


How long after taking brilinta can I smoke weed or take edibles?


To avoid any residual toxicity it is advisable to wait until the brilinta has totally cleared your system before taking weed, even in small quantities.


Overdose on brilinta and weed


In the case of Overdose on brilinta or if you are worried after mixing brilinta and weed, call a first responder or proceed to the nearest Emergency Room immediately.


If you are worried about someone who has taken too much brilinta or mixed weed with brilinta then call a first responder or take them to get immediate medical help. The best place for you or someone you care about in the case of a medical emergency is under medical supervision. Be sure to tell the medical team that there is a mix of brilinta and weed in their system.


Excessive Weed intake and result in scromiting, chs, and anxiety disorder.  It is advisable to quit vaping weed if you are feeling these symptoms.

Mixing brilinta and weed and antidepressants


Weed users feeling depressed and anxious may be prescribed antidepressant medication. There are some antidepressant users who also use brilinta and weed. These individuals may not realize that there are side effects and consequences to consuming both brilinta, marijuana and a range of antidepressants.


Studies on weed, brilinta and antidepressants is almost nil. The reason for so little information on the side effects of the two is mostly down to marijuana being illegal in most places – although a number of states in the United States have legalized the drug.


Self-medicating with Weed and brilinta


A lot of people suffer from depression caused by weed and brilinta. How many? According to Anxiety and Depression Association of America (ADAA), in any given year, it is estimated that nearly 16 million adults experience depression. Unfortunately, that number is likely to be wrong due to under reporting. Many people do not report suffering from depression because they do not want to be looked at as suffering from a mental illness. The stigmas around mental health continue and people do not want to be labeled as depressed.


Potential side effects from mixing brilinta and weed


Quitting weed to take brilinta


Medical professionals say an individual prescribed or taking brilinta should not stop using weed cold turkey.  Withdrawal symptoms can be significant. Heavy pot users should especially avoid going cold turkey. The side effects of withdrawal from weed include anxiety, irritability, loss of sleep, change of appetite, and depression by quitting weed cold turkey and starting to take brilinta.


A person beginning to use brilinta should cut back on weed slowly. While reducing the amount of weed use, combine it with mindfulness techniques and/or yoga. Experts stress that non-medication can greatly improve a person’s mood.


Weed and brilinta can affect a person in various ways. Different types of marijuana produce different side effects. Side effects of weed and brilinta may include:


  • loss of motor skills
  • poor or lack of coordination
  • lowered blood pressure
  • short-term memory loss
  • increased heart rate
  • increased blood pressure
  • anxiety
  • paranoia
  • increased energy
  • increased motivation


Mixing brilinta and weed can also produce hallucinations in users. This makes marijuana a hallucinogenic for some users. Weed creates different side effects in different people, making it a very potent drug. Now, mixing brilinta or other mental health drugs with weed can cause even more unwanted side effects.


Mixing drugs and weed conclusion


Long-term weed use can make depression and anxiety worse. In addition, using marijuana can prevent brilinta from working to their full potential33.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from Weed consumption should be reduced gradually to get the most out of prescription medication. Marijuana is a drug and it is harmful to individual’s long-term health. Weed has many side effects and the consequences are different to each person who uses it, especially when mixed with brilinta.


If you take brilinta, and also drink Alcohol or MDMA, you can research the effects of brilinta and Alcohol , brilinta and Cocaine as well as brilinta and MDMA here.


To find the effects of other drugs and weed refer to our Weed and Other Drugs Index A to L or our Weed and Other Drugs Index M-Z.

Or you could find what you are looking for in our Alcohol and Interactions with Other Drugs index A to L or Alcohol and Interactions with Other Drugs index M to Z , Cocaine and Interactions with Other Drugs index A to L or Cocaine and Interactions with Other Drugs index M to Z or our MDMA and Interactions with Other Drugs Index A to L or MDMA and Interactions with Other Drugs Index M to Z.


brilinta and Weed

brilinta and Weed

Counselling for Weed Addiction; Low Cost - Qualified Therapists - Available Now - 20% Off

We may make a commission if you purchase anything via the adverts or links on this page.


Betterhelp is for anyone suffering from mental health issues. Whether you suffer from anxiety, depression, weed addiction, eating disorders, or just need someone to speak to, Betterhelp can pair you with a qualified therapist.


In the wake of the pandemic, an increasing number of people have sought out therapeutic and conseling services to help with weed cessation. Better Help has seen a massive rise in people seeking help over the last two to three years.


If you or someone you care about is smoking or ingesting a level of weed that makes their life become unmanageable, Betterhelp has counselors and therapists on hand to help for less that $90 per week.

Specializations | Burnout, Anxiety, Depression, Stress, Anger Management, Dependencies, Grief, Seasonal Depressive Disorder, Life Crisis, Smoking Cessation, Weed Cessation (among others)


Betterhelp Cost | The standard fee for BetterHelp therapy is only $60 to $90 per week or $240 to $360 per month.


Key Takeaways |

  • Largest online therapy platform
  • Low cost
  • Good for stopping weed
  • Messaging
  • Live video
  • Phone calls
  • Live chat
  • No lock in contracts
  • Cancel anytime
  • Licensed and accredited therapists


Discounts Available | We have negotiated a generous 20% discount for readers of our website. Press Here to get 20% Off


  • 1
    1.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from
  • 2
    2.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from
  • 3
    3.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from